Gastro Esophageal RefluxNCT07563491
Comparison of Esomeprazole Versus Vonoprazan in Gastroesophageal Reflux Disease
A study testing Esomeprazole and Vonoprazan in people with Gastro Esophageal Reflux, run by Muhammad Aamir Latif at 1 site in Pakistan.
Trial summary
Local literature is deprived of data comparing the effectiveness of esomeprazole and vonoprazan in patients with gastroesophageal reflux disease (GERD). This study was planned with the objective of comparing the effectiveness of esomeprazole versus vonoprazan in patients diagnosed with GERD. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Gastro Esophageal Reflux
- What is being tested?
- Esomeprazole and Vonoprazan
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 824 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Jan 2025to 30 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Any gender
- Aged 18 to 65 years
- Presenting with GERD
Who cannot join
- Patients with hepatic, renal, respiratory, or cardiac disease accessed on history and medical records.
- Any previous history of malignancy accessed from medical records.
- Pregnancy and Lactation
- Currently using histamine-2 receptor antagonists, antacids, gastrointestinal motility stimulants, and steroids.
- History of drug allergy to proton pump Inhibitors (PPIs).
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Allama Iqbal teaching hospital
Dera Ghazi Khan, Punjab Province, 32200
About this study
Official title: Comparison of Effectiveness in Patients of Gastroesophageal Reflux Disease Taking Esomeprazole Versus Vonoprazan.
Local literature is deprived of data comparing the effectiveness of esomeprazole and vonoprazan in patients with gastroesophageal reflux disease (GERD). This study was planned with the objective of comparing the effectiveness of esomeprazole versus vonoprazan in patients diagnosed with GERD.
Read the detailed description
Addressing the pressing need for an in-depth understanding and comparison of treatment options for the escalating prevalence of GERD, a condition significantly impacting patients' quality of life, is crucial. The study's results would not only provide local data, but also help doctors choose between esomeprazole and vonoprazan as the best treatment option. This would improve patient care and help doctors make better decisions, which would ultimately lead to better management of GERD and the overall health of patients.
- Conditions
- Gastro Esophageal Reflux
- Being tested
- Esomeprazole, Vonoprazan
- Medical subject headings
- Gastroesophageal Reflux
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EsomeprazoleDrug
Patients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks.
VonoprazanDrug
Patients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Group-A | Experimental | Patients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks. Receives: Drug: Esomeprazole |
| Group-B | Experimental | Patients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks. Receives: Drug: Vonoprazan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sufficient relief
The frequency of patients who achieved sufficient relief was noted.
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2026
- Study start1 Jan 2025
- Primary completion30 Sep 2025
- Study completion30 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastro Esophageal RefluxStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 824 participants (actual)
Sponsor and investigators
- Lead sponsor
- Muhammad Aamir Latif
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Muhammad Aamir Latif, RESnTEC, Institute of Research
- Investigators
- Faraz Ahmad, Principal investigator, Allama Iqbal teaching hospital Dera Ghazi KhanMujahid Iqbal, FCPS, Study director, Allama Iqbal teaching hospital Dera Ghazi Khan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07563491
- Sponsor's protocol ID
- Dr-Faraz-DGK
- Status last verified
- Apr 2026
- First submitted
- 25 Apr 2026
- Last updated
- 4 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data can be shared on a reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Effectiveness in Patients of Gastroesophageal Reflux Disease Taking Esomeprazole Versus Vonoprazan.
- ClinicalTrials.gov ID
- NCT07563491
- Acronym / sponsor ID
- Dr-Faraz-DGK
- Conditions
- Gastro Esophageal Reflux
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 824 participants (actual)
- Lead sponsor
- Muhammad Aamir LatifUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 4 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Local literature is deprived of data comparing the effectiveness of esomeprazole and vonoprazan in patients with gastroesophageal reflux disease (GERD). This study was planned with the objective of comparing the effectiveness of esomeprazole versus vonoprazan in patients diagnosed with GERD.
Detailed description
Addressing the pressing need for an in-depth understanding and comparison of treatment options for the escalating prevalence of GERD, a condition significantly impacting patients' quality of life, is crucial. The study's results would not only provide local data, but also help doctors choose between esomeprazole and vonoprazan as the best treatment option. This would improve patient care and help doctors make better decisions, which would ultimately lead to better management of GERD and the overall health of patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group-A | Experimental | Drug: EsomeprazolePatients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks. |
| Group-B | Experimental | Drug: VonoprazanPatients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Any gender
- Aged 18 to 65 years
- Presenting with GERD
Key exclusion criteria (5 listed)
- Patients with hepatic, renal, respiratory, or cardiac disease accessed on history and medical records.
- Any previous history of malignancy accessed from medical records.
- Pregnancy and Lactation
- Currently using histamine-2 receptor antagonists, antacids, gastrointestinal motility stimulants, and steroids.
- History of drug allergy to proton pump Inhibitors (PPIs).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EsomeprazolePatients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks. | Drug | Group-A |
| VonoprazanPatients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks. | Drug | Group-B |
Primary outcome
Sufficient relief
Time frame: 4 weeks
The frequency of patients who achieved sufficient relief was noted.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
- Individual participant dataSharing planned: No. Data can be shared on a reasonable request.
Related trials for Gastro Esophageal Reflux
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Recruiting
SPADE Clinical Trial.
Early Gastric Cancer, Adenocarcinoma of the Stomach
Enrolling by invitation
Endoscopic Treatment of Gastroesophageal Reflux Disease
Gastro Esophageal Reflux Disease
Enrolling by invitationObservational study
Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device
Gastro Esophageal Reflux
RecruitingObservational study
Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU
Stress Ulcers, Reflux Episodes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Faraz Ahmad principal investigator
Allama Iqbal teaching hospital Dera Ghazi Khan
Mujahid Iqbal, FCPS study director
Allama Iqbal teaching hospital Dera Ghazi Khan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Esomeprazole and Vonoprazan in people with Gastro Esophageal Reflux, run by Muhammad Aamir Latif at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sufficient relief (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.